Barclays Downgrades Halozyme Therapeutics (HALO) to Equalweight
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $37.81 -0.55%
Rating Summary:
16 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Rating Summary:
16 Buy, 5 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 17 | Down: 14 | New: 17
Join SI Premium – FREE
Barclays downgraded Halozyme Therapeutics (NASDAQ: HALO) from Overweight to Equalweight with a price target of $8.00 (from $9.00).
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $7.32 yesterday.
For an analyst ratings summary and ratings history on Halozyme Therapeutics click here. For more ratings news on Halozyme Therapeutics click here.
Shares of Halozyme Therapeutics closed at $7.32 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Downgrades Shield Therapeutics PLC (STX:LN) to Hold
- Citi Downgrades Arch Coal (ARCH) to Neutral
- Morgan Stanley Downgrades Etsy (ETSY) to Underweight
Create E-mail Alert Related Categories
DowngradesRelated Entities
BarclaysSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
